Amtrust International Underwriters DAC v. 180 Life Sciences Corp.

  1. February 13, 2024

    Insurers Must Pay Pharma Co. Defense Costs In SEC Probe

    A drug development company formed by a merger is entitled to insurance payments for expenses it paid two of its former officers in connection with federal subpoenas because the insurer failed to show that an exclusion applied, a California federal judge ruled Monday.

  2. August 28, 2023

    Drug Co. Says Exclusion Doesn't Bar Subpoena Coverage

    A drug development company born out of a merger is once again seeking coverage for expenses it advanced to two of its former officers in connection with U.S. Securities and Exchange Commission subpoenas, telling a California federal court that a change-in-control exclusion is inapplicable.

  3. April 24, 2023

    Exclusion Bars Subpoena Expenses Coverage, Judge Says

    A drug development company born out of a merger does not have coverage for expenses it advanced to two of its former officers in connection with U.S. Securities and Exchange Commission subpoenas, a California federal court ruled, saying the company hasn't shown that a change-in-control exclusion is inapplicable.

  4. December 21, 2022

    Drug Developer Not Covered For SEC Probe, Insurers Say

    A drug development company born out of a merger doesn't have coverage for costs incurred from responding to U.S. Securities and Exchange Commission subpoenas, insurers told a California federal court, arguing that the new company doesn't qualify as a named insured under the prior firm's directors and officers policy.

  5. November 23, 2022

    Insurers Must Cover SEC Investigation, Drug Developer Says

    A drug development company born out of a merger asked a California federal court to find that directors and officers' insurance held under its former name must cover costs incurred by former leaders forced to respond to U.S. Securities and Exchange Commission subpoenas.